Skip to main content

Advertisement

SpringerLink
Log in

Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in treatment-naïve women with overactive bladder (OAB).

Methods

Women being treated with mirabegron 50 mg were allocated to MS and non-MS groups, and the efficacy of treatment of OAB was compared using the OAB symptom score (OABSS) and a 3-day voiding diary before and 12 weeks after starting treatment. The Wilcoxon signed-rank and Mann-Whitney U tests and multivariate logistic regression were used for statistical analyses, and a p-value < 0.05 was considered to represent statistical significance.

Results

Of the 197 patients who completed the trial, 43 (23.9%) had MS. After 12 weeks of mirabegron treatment, both the MS and non-MS groups showed significant improvements in OABSS score, the number of incontinence episodes/24 h, the number of micturition episodes/24 h, and the number of episodes of urgency/24 h. The factors associated with clinically important differences in OABSS were the presence of hyperglycemia (odds ratio 2.43, 95% confidence interval [CI] 1.05–5.60) and OABSS score at baseline (odds ratio 1.23, 95% CI 1.09–1.39).

Conclusions

Mirabegron is effective in patients with and without MS, and comorbid hyperglycemia and severe OAB symptoms before treatment are predictors of the efficacy of mirabegron treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.

    Article  PubMed  Google Scholar 

  2. Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005;96:1314–8.

    Article  PubMed  Google Scholar 

  3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.

    Article  PubMed  Google Scholar 

  4. Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75:491–500.

    Article  PubMed  Google Scholar 

  5. Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome. BMJ. 2012;344:e2365.

    Article  PubMed  Google Scholar 

  6. Takahashi S, Takei M, Asakura H, Gotoh M, Ishizuka O, Kato K, et al. Clinical guidelines for female lower urinary tract symptoms (second edition). Int J Urol. 2021;28:474–92.

    Article  PubMed  Google Scholar 

  7. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642–7.

    Article  CAS  PubMed  Google Scholar 

  8. Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77:119–28. https://doi.org/10.1016/j.eururo.2019.09.024.

    Article  CAS  PubMed  Google Scholar 

  9. The Ministry of Health, Labour, and Welfare of Japan. (2020) The National Health and Nutrition Survey in Japan 2019.https://www.mhlw.go.jp/content/000710991.pdf. Accessed 30 Jan 2022.

  10. Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75:988–1000.

    Article  PubMed  Google Scholar 

  11. Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69:199–217.

    Article  CAS  PubMed  Google Scholar 

  12. Richter HE, Amundsen CL, Erickson SW, Jelovsek JE, Komesu Y, Chermansky C, NICHD Pelvic Floor Disorders Network, et al. Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence. J Urol. 2017;198:890–6. https://doi.org/10.1016/j.juro.2017.04.103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36:2123–31. https://doi.org/10.1002/nau.23256.

    Article  CAS  PubMed  Google Scholar 

  14. Krhut J, Martan A, Zachoval R, Hanuš T, Švabík K, Zvara P. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur J Obstet Gynecol Reprod Biol. 2016;196:64–8. https://doi.org/10.1016/j.ejogrb.2015.11.018.

    Article  CAS  PubMed  Google Scholar 

  15. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology. 2011;77:60–4.

    Article  PubMed  Google Scholar 

  16. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al. Neurogenic Bladder Society Clinical guidelines for overactive bladder. Int J Urol. 2009;16:126–42.

    Article  CAS  PubMed  Google Scholar 

  17. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nihon Naika Gakkai Zasshi. 2005;94:794–809.

    Google Scholar 

  18. Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011;78:768–73.

    Article  PubMed  Google Scholar 

  19. Serati M, ULM M, Sorice P, Cantaluppi S, Agrò EF, Ghezzi F, Publication Committee of the Italian Society of Urodynamics. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder? Int Urogynecol J. 2017;28:1033–9. https://doi.org/10.1007/s00192-016-3219-x.

    Article  PubMed  Google Scholar 

  20. Cardozo L, Herschorn S, Snijder R, Siddiqui E, Chapple CR. Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder? Int Urogynecol J. 2017;28:477–88. https://doi.org/10.1007/s00192-016-3130-5.

    Article  PubMed  Google Scholar 

  21. Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64:1287–93. https://doi.org/10.1111/j.1742-1241.2010.02442.x.

    Article  CAS  PubMed  Google Scholar 

  22. Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn. 2010;29:551–4. https://doi.org/10.1002/nau.20787.

    Article  PubMed  Google Scholar 

  23. Khullar V, Sexton CC, Thompson CL, Milsom I, Bitoun CE, Coyne KS. The relationship between BMI and urinary incontinence subgroups: results from EpiLUTS. Neurourol Urodyn. 2014;33:392–9. https://doi.org/10.1002/nau.22428.

    Article  PubMed  Google Scholar 

  24. Azadzoi KM, Siroky MB. Mechanisms of lower urinary tract symptoms in pelvic ischemia. J Biochem Pharmacol Res. 2013;1:64–74.

    PubMed  PubMed Central  Google Scholar 

  25. Krhut J, Martan A, Zachoval R, Hanus T, Horcicka L, Svabík K, Zvara P. Is it possible to cure the symptoms of the overactive bladder in women? Int Urol Nephrol. 2018;50:433–9. https://doi.org/10.1007/s11255-017-1777-6.

    Article  PubMed  Google Scholar 

  26. Finlin BS, Memetimin H, Zhu B, Confides AL, Vekaria HJ, El Khouli RH, et al. The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest. 2020;130:2319–31. https://doi.org/10.1172/JCI134892.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35:827–38. https://doi.org/10.1007/s00345-016-1908-1.

    Article  CAS  PubMed  Google Scholar 

  28. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63. https://doi.org/10.1016/j.juro.2012.09.079.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mark Cleasby, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka-shi, Tokyo, 181-8611, Japan

    Manami Kinjo, Kazuki Masuda, Yu Nakamura, Satoru Taguchi, Mitsuhiro Tambo & Hiroshi Fukuhara

Authors
  1. Manami Kinjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuki Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoru Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuhiro Tambo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manami Kinjo.

Ethics declarations

Conflicts of interest

None

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kinjo, M., Masuda, K., Nakamura, Y. et al. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?. Int Urogynecol J 34, 853–859 (2023). https://doi.org/10.1007/s00192-022-05261-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-022-05261-y

Keywords

Search

Navigation